What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2353.png

 

Spleen Reduction

 

Each 10% reduction in spleen length was associated with 9% reduction in risk of death (HR=0.91; 95%CI: 0.84-0.99; P=0.02)1

 

Reduction in spleen size was predictive for improved overall survival2

Group 2455.png

Mean percentage change in spleen volume3

Layer_13.png

  • 53.4% of patients in the ruxolitinib arm achieved a ≥ 35% reduction in spleen volume at any time on treatment4

  • 97.1% of patients with post baseline spleen assessments experienced a clinical benefit with some degree of spleen volume4

  • 75.6% of patients who crossed over to ruxolitinib treatment from the BAT arm experienced reduction in spleen volume from their last pre-crossover assessment4

Early intervention with JAKAVI may result in higher rates of spleen response3

Predictors of spleen response with JAKAVI1

Layer_14.png

Earlier treatment with JAKAVI increased the probability of spleen response by almost

Frame 427318893.png

For JAKAVI-MF Abbreviated prescribing information

PDF
View

References

  1. Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139-1145. 

  2. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E. Long-term outcomes of 107 patients with myelofibrosisreceiving JAK1􀳦JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, The Journal of the American Society of Hematology. 2012 Aug 9;120(6):1202-9. 

  3. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047–53 

  4. Palandri F, Palumbo GA, Bonifacio M, et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget. 2017;8(45):79073-79086

Approved by Egyptian Drug Authority: HF0424OA4703/102025. Invalidation date: 17/12/2025.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg.

Jakavi QR

HF0424OA4703/102025 17/12/2025

 

        

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting